<html><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta http-equiv="Content-Style-Type" content="text/css" /><meta name="generator" content="Aspose.Words for .NET 13.4.0.0" /><title>The Academy of Medical Sciences’</title></head><body><div><p style="margin:0pt"><span style="font-family:Verdana; font-size:10pt">&#xa0;</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 216pt; text-align:center; text-indent:-216pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Written evidence submitted by </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">The Academy of Medical Sciences’ (AMR0054)</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 216pt; text-align:justify; text-indent:-216pt"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 216pt; text-align:justify; text-indent:-216pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">Summary</span><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps"> </span></p><p style="font-size:11pt; line-height:115%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="font-family:Symbol; font-size:11pt; line-height:14pt; margin:0pt 0pt 0pt 27.91pt; padding-left:7.79pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Antimicrobial resistance (AMR) is an issue which currently has an enormous global impact; the </span><span style="font-family:'Times New Roman'; font-size:11pt">severity of which will only increase if this is not addressed</span><span style="font-family:'Times New Roman'; font-size:11pt"> appropriately</span><span style="font-family:'Times New Roman'; font-size:11pt">. If current trends continue there is the threat of a return to a pre-anti</span><span style="font-family:'Times New Roman'; font-size:11pt">microbial</span><span style="font-family:'Times New Roman'; font-size:11pt"> era.</span></li><li style="font-family:Symbol; font-size:11pt; line-height:14pt; margin:0pt 0pt 0pt 27.91pt; padding-left:7.79pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">The Academy acknowledges the degree of excellent research that UK and international medical </span><span style="font-family:'Times New Roman'; font-size:11pt">scientists are performing in this area, but many significant gaps in our knowledge of AMR remain and can only be addressed with increased and sustained funding for research. </span></li><li style="font-family:Symbol; font-size:11pt; line-height:14pt; margin:0pt 0pt 0pt 27.91pt; padding-left:7.79pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Pharmaceutical companies cannot be expected to be solely responsible for the prod</span><span style="font-family:'Times New Roman'; font-size:11pt">uction of new antimicrobial therapies; governments need to develop a strong role in facilitating this, particularly by funding intermediary clinical trials. </span></li><li style="font-family:Symbol; font-size:11pt; line-height:14pt; margin:0pt 0pt 0pt 27.91pt; padding-left:7.79pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Increased public awareness about AMR and antimicrobial treatment use, and education of clinicians,</span><span style="font-family:'Times New Roman'; font-size:11pt"> general practitioners and veterinary surgeons about antimicrobial ‘stewardship’ (good practice for prescribing and using therapies)</span><span style="font-family:'Times New Roman'; font-size:11pt">,</span><span style="font-family:'Times New Roman'; font-size:11pt"> are vital. This should reduce the prescription of antimicrobial treatments to those who will not benefit from them, and im</span><span style="font-family:'Times New Roman'; font-size:11pt">prove adherence to prescriptions of those </span><span style="font-family:'Times New Roman'; font-size:11pt">who</span><span style="font-family:'Times New Roman'; font-size:11pt"> would. </span></li><li style="font-family:Symbol; font-size:11pt; line-height:14pt; margin:0pt 0pt 0pt 27.91pt; padding-left:7.79pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">International co-ordination and efforts to address AMR are paramount.</span></li><li style="font-family:Symbol; font-size:11pt; line-height:14pt; margin:0pt 0pt 0pt 27.91pt; padding-left:7.79pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">The Academy welcomes the UK Department of Health’s ‘UK Five Year Antimicrobial Resistanc</span><span style="font-family:'Times New Roman'; font-size:11pt">e Strategy 2013-2018’, and believes </span><span style="font-family:'Times New Roman'; font-size:11pt">it addre</span><span style="font-family:'Times New Roman'; font-size:11pt">sses many of the issues that are central to the problem of AMR in the UK.</span><a name="_ftnref1"></a><a href="#_ftn1">[1]</a></li><li style="font-family:Symbol; font-size:11pt; line-height:14pt; margin:0pt 0pt 0pt 27.91pt; padding-left:7.79pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">However, the strategy should place more emphasis on some critical issues including the role and use of antimicrobials in veterinary medicine and agriculture, how to incentivise the </span><span style="font-family:'Times New Roman'; font-size:11pt">development of new therapies by pharmaceutical companies, global coordination to tackle the issue, sufficient funding allocation for AMR-related research, and the role of vaccines and diagnostics.</span><a name="_GoBack"></a></li></ul><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 216pt; text-align:justify; text-indent:-216pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">Introduction </span></p><p style="font-size:11pt; line-height:115%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; line-height:14pt; margin:0pt 0pt 0pt 31.1pt; padding-left:4.6pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">The Academy of Medical Sciences</span><span style="font-family:'Times New Roman'; font-size:11pt"> promotes advances in medical science and campaigns to ensure that these are translated into healthcare benefits for society.</span><span style="background-color:#ffffff; color:#666666; font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">The Academy welcomes the production of the UK Department of Health’s (DH) ‘</span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">UK Five Year Antimicrobial Resistance Strategy for </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">2013-2018</span><span style="font-family:'Times New Roman'; font-size:11pt">’ a</span><span style="background-color:#ffffff; font-family:'Times New Roman'; font-size:11pt">n</span><span style="font-family:'Times New Roman'; font-size:11pt">d commends the DH for creating a plan to tackle such an important issue.</span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">1</span><span style="font-family:'Times New Roman'; font-size:11pt"> In particular, the role of Professor Dame Sally Davies DBE FMedSci as a necessary champion of this cause should not be understated, given the need to raise awareness of </span><span style="font-family:'Times New Roman'; font-size:11pt">the severity of the issue in the UK and internationally. We also value the Commons Science and Technology Select Committee’s inquiry on antimicrobial resistance (AMR), which will help to determine whether the issue is being addressed appropriately. We have</span><span style="font-family:'Times New Roman'; font-size:11pt"> provided answers to the six questions posed by the committee, with a particular focus on current and future research issues (questions two, three, five and six) which are central to the Academy’s expertise. We would be willing to provide additional oral e</span><span style="font-family:'Times New Roman'; font-size:11pt">vidence to the committee’s inquiry if requested.   </span></li></ol><p style="line-height:14pt; margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="line-height:14pt; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="line-height:14pt; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 216pt; text-align:justify; text-indent:-216pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">How has antimicrobial resistance developed in the past decade?</span></p><p style="line-height:14pt; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="2" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; line-height:14pt; margin:0pt 0pt 0pt 31.1pt; padding-left:4.6pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Anti</span><span style="font-family:'Times New Roman'; font-size:11pt">microbials</span><span style="font-family:'Times New Roman'; font-size:11pt"> are one of the great discoveries of the 20</span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">th</span><span style="font-family:'Times New Roman'; font-size:11pt"> century, preserving the lives of millions of people worldwide. However, follo</span><span style="font-family:'Times New Roman'; font-size:11pt">wing their rapid development between the 1940s and 1980s, antibiotics and other antimicrobial treatments have been used widely and indiscriminately in both humans and </span><span style="font-family:'Times New Roman'; font-size:11pt">other </span><span style="font-family:'Times New Roman'; font-size:11pt">animals and the resultant misuse and over-use has led to </span><span style="font-family:'Times New Roman'; font-size:11pt">the selection of anti</span><span style="font-family:'Times New Roman'; font-size:11pt">micro</span><span style="font-family:'Times New Roman'; font-size:11pt">bial</span><span style="font-family:'Times New Roman'; font-size:11pt"> resistant and multi-resistant organisms</span><span style="font-family:'Times New Roman'; font-size:11pt">. In particular, previously curable infectious diseases, such as tuberculosis (TB), are now resurgent public health </span><span style="font-family:'Times New Roman'; font-size:11pt">problems</span><span style="font-family:'Times New Roman'; font-size:11pt"> as multi-drug resistant </span><span style="font-family:'Times New Roman'; font-size:11pt">variants</span><span style="font-family:'Times New Roman'; font-size:11pt"> emerge, leading to untreatable infections. Organisms r</span><span style="font-family:'Times New Roman'; font-size:11pt">esistant to all available drugs have already been identified, and their emergence and spread could res</span><span style="font-family:'Times New Roman'; font-size:11pt">ult in a return to the pre-antimicrobial</span><span style="font-family:'Times New Roman'; font-size:11pt"> era.</span><a name="_ftnref2"></a><a href="#_ftn2">[2]</a><span style="font-family:'Times New Roman'; font-size:11pt"> The impact of these drug-resistant organisms is far-reaching, leading not only to increased mortality from </span><span style="font-family:'Times New Roman'; font-size:11pt">infectious diseases, but also compromising modern medicine as a whole by affecting the efficacy of surgery, treatment of organ transplant patients, cancer patients, pre-term infants and all those reliant on immunosuppressant therapies. </span></li></ol><p style="line-height:14pt; margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="3" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; line-height:14pt; margin:0pt 0pt 0pt 31.1pt; padding-left:4.6pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Hospital-acquired </span><span style="font-family:'Times New Roman'; font-size:11pt">bacterial infections have increased this decade, with the NHS reporting that 6% of patients entering hospital required treatment for infection following their stay.</span><a name="_ftnref3"></a><a href="#_ftn3">[3]</a><span style="font-family:'Times New Roman'; font-size:11pt"> This figure is an improvement on previous years due to interventions put into place to ste</span><span style="font-family:'Times New Roman'; font-size:11pt">m the spread of methicillin resistant </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Staphylcoccus aureus </span><span style="font-family:'Times New Roman'; font-size:11pt">(MRSA)</span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">. </span><span style="font-family:'Times New Roman'; font-size:11pt">However, these interventions have done little to prevent the spread of drug resistant </span><span style="font-family:'Times New Roman'; font-size:11pt">variants</span><span style="font-family:'Times New Roman'; font-size:11pt"> of </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">E. coli </span><span style="font-family:'Times New Roman'; font-size:11pt">and </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Klebsiella</span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">. </span><span style="font-family:'Times New Roman'; font-size:11pt">Antimicrobial resistance has the potential to create a massive fina</span><span style="font-family:'Times New Roman'; font-size:11pt">ncial burden on the NHS, which will increase as organisms become gradually resistant to all available antimicrobials. </span></li></ol><p style="line-height:14pt; margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 216pt; text-align:justify; text-indent:-216pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">What are the gaps in our knowledge about antimicrobial resistance? </span></p><p style="font-size:11pt; line-height:115%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="4" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; line-height:14pt; margin:0pt 0pt 0pt 31.1pt; padding-left:4.6pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Despite excellent and productive research in many fields relating </span><span style="font-family:'Times New Roman'; font-size:11pt">to AMR (in which UK researchers are often world leading experts), research into new antimicrobial agents, the mechanisms of resistance and clinical research into antimicrobial practice </span><span style="font-family:'Times New Roman'; font-size:11pt">have</span><span style="font-family:'Times New Roman'; font-size:11pt"> been under-resourced and disproportionate to the increasing magnit</span><span style="font-family:'Times New Roman'; font-size:11pt">ude of the problem in the past several decades. There are therefore a significant number of areas in which our knowledge is lacking, ranging from basic science to the implementation and evaluation of response strategies, </span><span style="font-family:'Times New Roman'; font-size:11pt">as follows</span><span style="font-family:'Times New Roman'; font-size:11pt">: </span></li></ol><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="font-family:Symbol; font-size:11pt; line-height:14pt; margin:0pt 0pt 0pt 27.91pt; padding-left:7.79pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Basic Research: </span><span style="font-family:'Times New Roman'; font-size:11pt">there </span><span style="font-family:'Times New Roman'; font-size:11pt">are many gaps in the basic scientific knowledge underpinning AMR, including </span><span style="font-family:'Times New Roman'; font-size:11pt">understanding</span><span style="font-family:'Times New Roman'; font-size:11pt"> of</span><span style="font-family:'Times New Roman'; font-size:11pt"> the different </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">mechanisms</span><span style="font-family:'Times New Roman'; font-size:11pt"> by which resistance arises</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">(whether</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">by point mutation</span><span style="font-family:'Times New Roman'; font-size:11pt"> or by</span><span style="font-family:'Times New Roman'; font-size:11pt"> lateral transfer</span><span style="font-family:'Times New Roman'; font-size:11pt">)</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">and</span><span style="font-family:'Times New Roman'; font-size:11pt"> whether being resistant to antimicrobials </span><span style="font-family:'Times New Roman'; font-size:11pt">influences the </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">growth, proliferation </span><span style="font-family:'Times New Roman'; font-size:11pt">and</span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic"> pathogenicity </span><span style="font-family:'Times New Roman'; font-size:11pt">of microbes</span><span style="font-family:'Times New Roman'; font-size:11pt">. As a further </span><span style="font-family:'Times New Roman'; font-size:11pt">example, we currently know little about the huge numbers of microbial species </span><span style="font-family:'Times New Roman'; font-size:11pt">that</span><span style="font-family:'Times New Roman'; font-size:11pt"> cannot be cultured within a laboratory environment, including many of the bacteria present i</span><span style="font-family:'Times New Roman'; font-size:11pt">n the normal gut flora and commensal microbiota</span><span style="font-family:'Times New Roman'; font-size:11pt">,</span><span style="font-family:'Times New Roman'; font-size:11pt"> which </span><span style="font-family:'Times New Roman'; font-size:11pt">might</span><span style="font-family:'Times New Roman'; font-size:11pt"> act as a reservoir for AMR genes.</span></li><li style="font-family:Symbol; font-size:11pt; line-height:14pt; margin:0pt 0pt 0pt 27.91pt; padding-left:7.79pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Epidemiological data</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">about</span><span style="font-family:'Times New Roman'; font-size:11pt"> AMR organisms and treatments at several levels (locally, nationally, and internationally) can be inconsistent or non-existent and many more detailed studies are warranted. </span><span style="font-family:'Times New Roman'; font-size:11pt">In particular, two areas require more scrutiny:</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span></li><ul type="circle" style="margin:0pt; padding-left:0pt"><li style="font-family:'Courier New'; font-size:11pt; line-height:14pt; margin:0pt 0pt 0pt 65.6pt; padding-left:6.4pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Transmission:</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">t</span><span style="font-family:'Times New Roman'; font-size:11pt">he routes of transm</span><span style="font-family:'Times New Roman'; font-size:11pt">ission of </span><span style="font-family:'Times New Roman'; font-size:11pt">AMR</span><span style="font-family:'Times New Roman'; font-size:11pt"> infections, between humans, from animals to humans, and from humans to animals are not well studied. Understanding transmission of resistance genes </span><span style="font-family:'Times New Roman'; font-size:11pt">between microbes</span><span style="font-family:'Times New Roman'; font-size:11pt"> is also important.  </span></li><li style="font-family:'Courier New'; font-size:11pt; line-height:14pt; margin:0pt 0pt 0pt 65.6pt; padding-left:6.4pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Surveillance</span><span style="font-family:'Times New Roman'; font-size:11pt">: to prevent future AMR pandemics it is of t</span><span style="font-family:'Times New Roman'; font-size:11pt">he utmost importance </span><span style="font-family:'Times New Roman'; font-size:11pt">that </span><span style="font-family:'Times New Roman'; font-size:11pt">good quality incidence and surveillance data</span><span style="font-family:'Times New Roman'; font-size:11pt"> are obtained</span><span style="font-family:'Times New Roman'; font-size:11pt"> internationally, </span><span style="font-family:'Times New Roman'; font-size:11pt">particularly from developing countries, </span><span style="font-family:'Times New Roman'; font-size:11pt">whence</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">many</span><span style="font-family:'Times New Roman'; font-size:11pt"> AMR organisms </span><span style="font-family:'Times New Roman'; font-size:11pt">are likely to </span><span style="font-family:'Times New Roman'; font-size:11pt">originate</span><span style="font-family:'Times New Roman'; font-size:11pt"> and where surveillance capacity is lower than in more developed c</span><span style="font-family:'Times New Roman'; font-size:11pt">ountries</span><span style="font-family:'Times New Roman'; font-size:11pt">. </span></li></ul><li style="font-family:Symbol; font-size:11pt; line-height:14pt; margin:0pt 0pt 0pt 27.91pt; padding-left:7.79pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Clinical research</span><span style="font-family:'Times New Roman'; font-size:11pt"> including </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">intervention </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">studies</span><span style="font-family:'Times New Roman'; font-size:11pt">, </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">behavioural studies</span><span style="font-family:'Times New Roman'; font-size:11pt">, and </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">drug therapy duration studies</span><span style="font-family:'Times New Roman'; font-size:11pt"> would be advantageous to assess improvements needed in clinical practice for preventing future infections and deaths arising from AMR. </span></li><li style="font-family:Symbol; font-size:11pt; line-height:14pt; margin:0pt 0pt 0pt 28.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Current anti</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">microbial</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold"> use:</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">i</span><span style="font-family:'Times New Roman'; font-size:11pt">t is unclear whether halting the use of antimicrobial treatments that are losing their efficacy as a result of AMR would lead to the re-emergence of </span><span style="font-family:'Times New Roman'; font-size:11pt">susceptible</span><span style="font-family:'Times New Roman'; font-size:11pt"> organisms in populations of AMR organisms, and if and when treatmen</span><span style="font-family:'Times New Roman'; font-size:11pt">ts could be re-introduced. Data on the use of antimicrobial treatments in care settings in response to outbreaks of AMR organisms are scarce.</span></li><li style="font-family:Symbol; font-size:11pt; line-height:14pt; margin:0pt 0pt 0pt 28.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Diagnosis:</span><span style="font-family:'Times New Roman'; font-size:11pt"> t</span><span style="font-family:'Times New Roman'; font-size:11pt">here has been concern about the lack of consistency between the susceptibility of microbes to anti</span><span style="font-family:'Times New Roman'; font-size:11pt">micr</span><span style="font-family:'Times New Roman'; font-size:11pt">obials</span><span style="font-family:'Times New Roman'; font-size:11pt"> in laboratory testing compared to </span><span style="font-family:'Times New Roman'; font-size:11pt">susceptibility to treatments observed in patients, indicating that our current laboratory tests may not be accurately detecting AMR or that the microbes are inaccessible to antimicrobials in the patient. </span><span style="font-family:'Times New Roman'; font-size:11pt">AMR</span><span style="font-family:'Times New Roman'; font-size:11pt"> measure</span><span style="font-family:'Times New Roman'; font-size:11pt">d by laboratory assays</span><span style="font-family:'Times New Roman'; font-size:11pt"> is, by definition, an </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">in vitro</span><span style="font-family:'Times New Roman'; font-size:11pt"> phenomenon; therefore the</span><span style="font-family:'Times New Roman'; font-size:11pt"> precise clinical impact of AMR is</span><span style="font-family:'Times New Roman'; font-size:11pt"> potentially</span><span style="font-family:'Times New Roman'; font-size:11pt"> poorly defined. This is reflected in the lack of correlation between laboratory testing of microbes’ susceptibility to antimicrobi</span><span style="font-family:'Times New Roman'; font-size:11pt">als and clinical outcomes. For example, although penicillin resistant </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Streptococcus pneumoniae</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">is</span><span style="font-family:'Times New Roman'; font-size:11pt"> frequently reported </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">in vitro</span><span style="font-family:'Times New Roman'; font-size:11pt">, cases of treatment are rare when adequate doses of penicillin</span><span style="font-family:'Times New Roman'; font-size:11pt"> are used</span><span style="font-family:'Times New Roman'; font-size:11pt">, suggesting that the </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">in vitro</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">phenotype</span><span style="font-family:'Times New Roman'; font-size:11pt"> does not necessarily translate into a clinical effect</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span><a name="_ftnref4"></a><a href="#_ftn4">[4]</a></li></ul><p style="font-size:11pt; line-height:115%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><h2 style="font-weight:normal; line-height:14pt; margin:0pt 0pt 14pt; page-break-after:avoid; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">Is there sufficient research and investment into new antibiotics or other treatments and methods to ensure continued protection against infection? If not, how could this be rectified?  </span></h2><ol start="5" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; line-height:14pt; margin:0pt 0pt 0pt 31.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Resistance </span><span style="font-family:'Times New Roman'; font-size:11pt">to antimicrobial agents is a widespread threat to the future of human health. Continued and extensive research is required from basic science through to clinical and epidemiological studies</span><span style="font-family:'Times New Roman'; font-size:11pt">,</span><span style="font-family:'Times New Roman'; font-size:11pt"> and clinical trials of new treatments are required in order to fi</span><span style="font-family:'Times New Roman'; font-size:11pt">ll the gaps in our knowledge and comprehensively tackle the current and future burden of antimicrobial resistance </span><span style="font-family:'Times New Roman'; font-size:11pt">on</span><span style="font-family:'Times New Roman'; font-size:11pt"> human health. It is paramount that fundamental research that will lead to identification of novel drug compounds and anti-infective strateg</span><span style="font-family:'Times New Roman'; font-size:11pt">ies is funded sufficiently in order to increase the possibility of tackling AMR. </span></li></ol><p style="line-height:14pt; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="6" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; line-height:14pt; margin:0pt 0pt 0pt 31.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Excellent</span><span style="font-family:'Times New Roman'; font-size:11pt"> microbiological</span><span style="font-family:'Times New Roman'; font-size:11pt"> research is currently being conducted, including important consortium studies such as the Human Microbiome Project.</span><a name="_ftnref5"></a><a href="#_ftn5">[5]</a><span style="font-family:'Times New Roman'; font-size:11pt"> Results from t</span><span style="font-family:'Times New Roman'; font-size:11pt">his </span><span style="font-family:'Times New Roman'; font-size:11pt">may help to </span><span style="font-family:'Times New Roman'; font-size:11pt">add</span><span style="font-family:'Times New Roman'; font-size:11pt"> significantly</span><span style="font-family:'Times New Roman'; font-size:11pt"> to </span><span style="font-family:'Times New Roman'; font-size:11pt">our knowledge</span><span style="font-family:'Times New Roman'; font-size:11pt"> in several areas</span><span style="font-family:'Times New Roman'; font-size:11pt">, </span><span style="font-family:'Times New Roman'; font-size:11pt">including </span><span style="font-family:'Times New Roman'; font-size:11pt">identifying reservoirs of antibiotic resistan</span><span style="font-family:'Times New Roman'; font-size:11pt">t</span><span style="font-family:'Times New Roman'; font-size:11pt"> bacteria in the human microflora</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">and the introduction of microbiome data into epidemiological studies.</span><a name="_ftnref6"></a><a href="#_ftn6">[6]</a><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">,</span><a name="_ftnref7"></a><a href="#_ftn7">[7]</a><span style="font-family:'Times New Roman'; font-size:11pt"> Novel research approaches will help to mitigate many aspects </span><span style="font-family:'Times New Roman'; font-size:11pt">of the AMR problem: for example, increased genomics capability will allow point-of-care (POC) diagnostics to be employed to reduce the burden of AMR organisms in care settings.</span><span style="font-family:'Times New Roman'; font-size:11pt"> Importantly, the </span><span style="font-family:'Times New Roman'; font-size:11pt">informed application of such new knowledge (for example from microbial genomics) to clinical care will require that those delivering health care (for example clinical microbiologists</span><span style="font-family:'Times New Roman'; font-size:11pt"> and</span><span style="font-family:'Times New Roman'; font-size:11pt"> infectious disease physicians) have received adequate training in its</span><span style="font-family:'Times New Roman'; font-size:11pt"> interpretation and use in clinical practice</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span></li></ol><p style="line-height:14pt; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="7" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; line-height:14pt; margin:0pt 0pt 0pt 31.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">A large </span><span style="font-family:'Times New Roman'; font-size:11pt">amount</span><span style="font-family:'Times New Roman'; font-size:11pt"> of research is focussed on the development of new antimicrobials. However, the AMR problem is one that can be tackled in a number of ways and investment should not be focussed solely on developm</span><span style="font-family:'Times New Roman'; font-size:11pt">ent of novel antimicrobial drugs</span><span style="font-family:'Times New Roman'; font-size:11pt">. It should also include the development </span><span style="font-family:'Times New Roman'; font-size:11pt">of vaccines to allow </span><span style="font-family:'Times New Roman'; font-size:11pt">for the </span><span style="font-family:'Times New Roman'; font-size:11pt">prevention</span><span style="font-family:'Times New Roman'; font-size:11pt"> of infections,</span><span style="font-family:'Times New Roman'; font-size:11pt"> and</span><span style="font-family:'Times New Roman'; font-size:11pt"> diagnostics to allow </span><span style="font-family:'Times New Roman'; font-size:11pt">for </span><span style="font-family:'Times New Roman'; font-size:11pt">quick and more accurate</span><span style="font-family:'Times New Roman'; font-size:11pt"> treatment</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">Vaccines have historically been used for bacterial infections</span><span style="font-family:'Times New Roman'; font-size:11pt">,</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">such as </span><span style="font-family:'Times New Roman'; font-size:11pt">TB</span><span style="font-family:'Times New Roman'; font-size:11pt">,</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">for</span><span style="font-family:'Times New Roman'; font-size:11pt"> prevent</span><span style="font-family:'Times New Roman'; font-size:11pt">ing</span><span style="font-family:'Times New Roman'; font-size:11pt"> disease</span><span style="font-family:'Times New Roman'; font-size:11pt"> occurrence</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">and</span><span style="font-family:'Times New Roman'; font-size:11pt"> for</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">help</span><span style="font-family:'Times New Roman'; font-size:11pt">ing</span><span style="font-family:'Times New Roman'; font-size:11pt"> to</span><span style="font-family:'Times New Roman'; font-size:11pt"> establish herd immunity.</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">I</span><span style="font-family:'Times New Roman'; font-size:11pt">nfections caused by</span><span style="font-family:'Times New Roman'; font-size:11pt"> many organisms, including</span><span style="font-family:'Times New Roman'; font-size:11pt"> Group B </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Streptococcus</span><span style="font-family:'Times New Roman'; font-size:11pt">, </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Chlamydia</span><span style="font-family:'Times New Roman'; font-size:11pt">, </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Helicobacter</span><span style="font-family:'Times New Roman'; font-size:11pt"> and </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">N</span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">eisseria </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">gonorrhoea</span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">e,</span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic"> </span><span style="font-family:'Times New Roman'; font-size:11pt">have all been suggested as important potential targets for new vaccines, </span><span style="font-family:'Times New Roman'; font-size:11pt">and improved vaccines are needed for TB</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span><a name="_ftnref8"></a><a href="#_ftn8">[8]</a><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">  </span></li></ol><p style="line-height:14pt; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="8" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; line-height:14pt; margin:0pt 0pt 0pt 31.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Despite being vital for the future </span><span style="font-family:'Times New Roman'; font-size:11pt">development</span><span style="font-family:'Times New Roman'; font-size:11pt"> of anti</span><span style="font-family:'Times New Roman'; font-size:11pt">microbials </span><span style="font-family:'Times New Roman'; font-size:11pt">and other treatments, many pharmaceutical companies have had to cease or downscale their antimicrobial development programmes for economic reasons. There is a lack of incentive for companies to produce treatments that </span><span style="font-family:'Times New Roman'; font-size:11pt">may</span><span style="font-family:'Times New Roman'; font-size:11pt"> quickly become obsolete due to dru</span><span style="font-family:'Times New Roman'; font-size:11pt">g resistance or that will be reserved for use as ‘last resort’ therapeutics. Collaborations between drug companies and governments, academia </span><span style="font-family:'Times New Roman'; font-size:11pt">and</span><span style="font-family:'Times New Roman'; font-size:11pt"> the NHS may allow these programmes to be resurrected or expanded.  </span></li></ol><p style="line-height:14pt; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="9" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; line-height:14pt; margin:0pt 0pt 0pt 31.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Furthermore, to encourage and incentivise </span><span style="font-family:'Times New Roman'; font-size:11pt">those in the field to bring new anti</span><span style="font-family:'Times New Roman'; font-size:11pt">microbials</span><span style="font-family:'Times New Roman'; font-size:11pt"> to the market, the production and sales of new antimicrobials should not be under-valued and under-priced, as it has been suggested was the case for previously developed antimicrobial treatments (following low</span><span style="font-family:'Times New Roman'; font-size:11pt"> production costs due to the former ease of antimicrobial production, and high demand from widespread, unreserved use). To do this, it will be necessary to highlight the cost to the healthcare system and subsequent loss of life if no solutions for combatin</span><span style="font-family:'Times New Roman'; font-size:11pt">g AMR are found. However, developing countries should not be prevented from obtaining access to new anti</span><span style="font-family:'Times New Roman'; font-size:11pt">microbials</span><span style="font-family:'Times New Roman'; font-size:11pt"> for economic reasons. </span></li></ol><p style="line-height:14pt; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="10" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; line-height:14pt; margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Incentives for drug development could include ‘push’ incentives such as early research subsidies to feed into the beg</span><span style="font-family:'Times New Roman'; font-size:11pt">inning of the drug discovery pipeline, financial support for clinical trials and harmonisation of drug regulation for new antimicrobials across Europe, Asia and the US, and ‘pull’ incentives such as patent extensions, minimum pricing agreement and risk-sha</span><span style="font-family:'Times New Roman'; font-size:11pt">ring reimbursement.  </span></li></ol><p style="line-height:14pt; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><h2 style="font-weight:normal; line-height:14pt; margin:0pt 0pt 14pt; page-break-after:avoid; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">What measures (including behavioural change) have been most effective in controlling the spread of resistant pathogens, and could such measures be used to control other pathogens? </span></h2><ol start="11" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; line-height:14pt; margin:0pt 0pt 0pt 35.7pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">It is impossible to eradicate AMR, since it is a n</span><span style="font-family:'Times New Roman'; font-size:11pt">atural evolutionary mechanism occurring in microbes. However, the action</span><span style="font-family:'Times New Roman'; font-size:11pt">s of humans influence</span><span style="font-family:'Times New Roman'; font-size:11pt"> the frequency and severity of drug resistant infections that are occurring and there are several steps that can be taken to protect existing antimicrobial treatme</span><span style="font-family:'Times New Roman'; font-size:11pt">nts for current and future generations. </span></li></ol><p style="font-size:11pt; line-height:115%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><h3 style="line-height:14pt; margin:0pt; page-break-after:avoid; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic; font-weight:bold">Awareness</span></h3><ol start="12" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; line-height:14pt; margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Public awareness of AMR will play a significant role in its control. A number of measures have been implemented in the UK to increase awareness of prudent antibiotic use. These include </span><span style="font-family:'Times New Roman'; font-size:11pt">the </span><span style="font-family:'Times New Roman'; font-size:11pt">European Antibi</span><span style="font-family:'Times New Roman'; font-size:11pt">otic Awareness Day, which </span><span style="font-family:'Times New Roman'; font-size:11pt">is</span><span style="font-family:'Times New Roman'; font-size:11pt"> a cheap and effective way of increasing public awareness of antibiotic resistance and proper use.</span><a name="_ftnref9"></a><a href="#_ftn9">[9]</a><span style="font-family:'Times New Roman'; font-size:11pt"> </span></li></ol><p style="line-height:14pt; margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="13" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; line-height:14pt; margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">However, the public expectation of receiving antimicrobials is still very high</span><a name="_ftnref10"></a><a href="#_ftn10">[10]</a><span style="font-family:'Times New Roman'; font-size:11pt">, and this places undue pressure on doctors to </span><span style="font-family:'Times New Roman'; font-size:11pt">prescribe anti</span><span style="font-family:'Times New Roman'; font-size:11pt">microbials </span><span style="font-family:'Times New Roman'; font-size:11pt">before an accurate diagnosis has been made. This practice of prescribing anti</span><span style="font-family:'Times New Roman'; font-size:11pt">microbials</span><span style="font-family:'Times New Roman'; font-size:11pt"> to meet expectations or to induce a placebo effect in patients should continue</span><span style="font-family:'Times New Roman'; font-size:11pt"> to be discouraged</span><span style="font-family:'Times New Roman'; font-size:11pt">. Increased campaigns to improve public awarene</span><span style="font-family:'Times New Roman'; font-size:11pt">ss of the </span><span style="font-family:'Times New Roman'; font-size:11pt">importance</span><span style="font-family:'Times New Roman'; font-size:11pt"> of antimicrobials and the detrimental effect of misuse would help to take pressure</span><span style="font-family:'Times New Roman'; font-size:11pt"> to prescribe</span><span style="font-family:'Times New Roman'; font-size:11pt"> off doctors. </span></li></ol><p style="line-height:14pt; margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><h3 style="line-height:14pt; margin:0pt; page-break-after:avoid; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic; font-weight:bold">Stewardship</span></h3><ol start="14" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; line-height:14pt; margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Many stewardship initiatives, including ‘Treat antibiotics responsibly, guidance and education tool’ (TARGET)</span><a name="_ftnref11"></a><a href="#_ftn11">[11]</a><span style="font-family:'Times New Roman'; font-size:11pt"> and ‘Stemming the tide of antibiotic resistance’ (STAR)</span><a name="_ftnref12"></a><a href="#_ftn12">[12]</a><span style="font-family:'Times New Roman'; font-size:11pt"> have been introduced in the UK to help promote better antibiotic prescribing practice by clinicians. However, the practice of prescription of anti</span><span style="font-family:'Times New Roman'; font-size:11pt">microbials</span><span style="font-family:'Times New Roman'; font-size:11pt"> to those who do not require them still re</span><span style="font-family:'Times New Roman'; font-size:11pt">mains a problem. </span><span style="font-family:'Times New Roman'; font-size:11pt">More extensive</span><span style="font-family:'Times New Roman'; font-size:11pt"> education of medical students </span><span style="font-family:'Times New Roman'; font-size:11pt">and doctors in training </span><span style="font-family:'Times New Roman'; font-size:11pt">on AMR issues would highlight the negative impact of bad </span><span style="font-family:'Times New Roman'; font-size:11pt">antimicrobial</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">prescribing practice for a future cadre of doctors.</span></li></ol><p style="line-height:14pt; margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="15" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; line-height:14pt; margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Stewardship campaigns should also be extended </span><span style="font-family:'Times New Roman'; font-size:11pt">to veterinary surgeons and animal keepers. Although antimicrobials can no longer be used in the UK or EU for </span><span style="font-family:'Times New Roman'; font-size:11pt">non-therapeutic use</span><span style="font-family:'Times New Roman'; font-size:11pt">, agriculture remains a major use</span><span style="font-family:'Times New Roman'; font-size:11pt">r</span><span style="font-family:'Times New Roman'; font-size:11pt"> of antimicrobials in the UK and </span><span style="font-family:'Times New Roman'; font-size:11pt">in other countries, where antimicrobials are used </span><span style="font-family:'Times New Roman'; font-size:11pt">without vet</span><span style="font-family:'Times New Roman'; font-size:11pt">erinary prescriptions</span><span style="font-family:'Times New Roman'; font-size:11pt">. The UK should act</span><span style="font-family:'Times New Roman'; font-size:11pt"> in collaboration with organisations such as the World Health Organization (WHO)</span><span style="font-family:'Times New Roman'; font-size:11pt">,</span><span style="font-family:'Times New Roman'; font-size:11pt"> the Food and Agriculture Organizat</span><span style="font-family:'Times New Roman'; font-size:11pt">ion of the United Nations (FAO)</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">and the </span><span style="font-family:'Times New Roman'; font-size:11pt">World Organisation for Animal Health</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">(OIE</span><span style="font-family:'Times New Roman'; font-size:11pt">) to actively encou</span><span style="font-family:'Times New Roman'; font-size:11pt">rage other nations to cease non-therapeutic use of antimicrobials </span><span style="font-family:'Times New Roman'; font-size:11pt">in agriculture</span><span style="font-family:'Times New Roman'; font-size:11pt">. Cost-effective alternatives to the widespread use of antimicrobials, such as procedures trialled in Denmark</span><span style="font-family:'Times New Roman'; font-size:11pt"> and elsewhere</span><span style="font-family:'Times New Roman'; font-size:11pt">, should be promoted.</span><a name="_ftnref13"></a><a href="#_ftn13">[13]</a><span style="font-family:'Times New Roman'; font-size:11pt"> </span></li></ol><p style="line-height:14pt; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="16" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; line-height:14pt; margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">An active effort from the UK</span><span style="font-family:'Times New Roman'; font-size:11pt"> should be made to encourage stewardship in other countries. Pressure is needed on a global scale to persuade countries which still allow antimicrobials to be sold without prescription,</span><span style="font-family:'Times New Roman'; font-size:11pt"> for</span><span style="font-family:'Times New Roman'; font-size:11pt"> both human and animal use, to ban these practi</span><span style="font-family:'Times New Roman'; font-size:11pt">c</span><span style="font-family:'Times New Roman'; font-size:11pt">es as they increase</span><span style="font-family:'Times New Roman'; font-size:11pt"> selection of AMR organisms. </span><span style="font-family:'Times New Roman'; font-size:11pt">I</span><span style="font-family:'Times New Roman'; font-size:11pt">nfectio</span><span style="font-family:'Times New Roman'; font-size:11pt">u</span><span style="font-family:'Times New Roman'; font-size:11pt">s</span><span style="font-family:'Times New Roman'; font-size:11pt"> AMR organisms</span><span style="font-family:'Times New Roman'; font-size:11pt"> that arise overseas </span><span style="font-family:'Times New Roman'; font-size:11pt">may well</span><span style="font-family:'Times New Roman'; font-size:11pt"> find their way into the UK via international tourism and travel</span><span style="font-family:'Times New Roman'; font-size:11pt"> (and vice versa)</span><span style="font-family:'Times New Roman'; font-size:11pt">. </span></li></ol><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="17" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; line-height:14pt; margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Another way to alleviate the problem of patient expectation and </span><span style="font-family:'Times New Roman'; font-size:11pt">to </span><span style="font-family:'Times New Roman'; font-size:11pt">aid prescribing stewardship would be the development of quick, cheap POC diagnostics to allow clinicians to distinguish accurately between various pathogenic infections whilst the patient is still in the clinic/GP office, therefore improving the prescripti</span><span style="font-family:'Times New Roman'; font-size:11pt">on accuracy of antimicrobial treatments and satisfying the needs of the patient. </span><span style="font-family:'Times New Roman'; font-size:11pt">Crucially, as in (6) above, this would need to be </span><span style="font-family:'Times New Roman'; font-size:11pt">accompanied by training of those using such POC diagnostics in the interpretation and informed use of the resultant diagnosti</span><span style="font-family:'Times New Roman'; font-size:11pt">c information.</span></li></ol><p style="line-height:14pt; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="18" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; line-height:14pt; margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Alongside better POC diagnostics, technology also has a role to play in better stewardship in prescribing. The Imperial Antibiotic Prescribing Policy (IAPP) smartphone app, for example, provides clinical decision support about antibiotics f</span><span style="font-family:'Times New Roman'; font-size:11pt">or clinicians at the point of care.</span><a name="_ftnref14"></a><a href="#_ftn14">[14]</a><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">This application has been warmly welcomed and adopted by clinicians, 96% of whom said it influenced their prescribing practice.</span></li></ol><p style="font-size:11pt; line-height:115%; margin:0pt; text-align:justify"><span style="background-color:#ffffff; color:#585858; font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">&#xa0;</span></p><p style="font-size:11pt; line-height:115%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">What global coordination and action is required to fight antimicrobial resistance and is </span><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">the UK contributing enough towards cross-border initiatives? </span></p><p style="font-size:11pt; line-height:115%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><ol start="19" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; line-height:14pt; margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">AMR is a worldwide problem and the increasing mobility of human populations, in addition to the large-scale transport of livestock and food internationally, has </span><span style="font-family:'Times New Roman'; font-size:11pt">played</span><span style="font-family:'Times New Roman'; font-size:11pt"> a pivotal role in the spr</span><span style="font-family:'Times New Roman'; font-size:11pt">ead of AMR. It is vital that global cooperation is established to stem the spread of AMR as and when it emerges, and it is critical for the UK to build upon its strong domestic strategy and stimulate global coordination and action to address AMR. The UK ca</span><span style="font-family:'Times New Roman'; font-size:11pt">n play an important role in global action on AMR because of the breadth of expertise in our universities, hospitals, general practices and pharmaceutical industry and also through the experience and expertise gained through the National Health Service, whi</span><span style="font-family:'Times New Roman'; font-size:11pt">ch can be used in global platforms to help countries with less well regulated health care systems, both in developed and developing nations.  </span></li></ol><p style="line-height:14pt; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="20" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; line-height:14pt; margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">AMR has yet to be adequately addressed on a global platform. It has been mentioned regularly at events such as t</span><span style="font-family:'Times New Roman'; font-size:11pt">he G8 Summit, but its importance has yet to be translated into a proportionate international response. It is critical that the severity of this issue is addressed by trans-national organisations such as WHO and the European Centre for Disease</span><span style="font-family:'Times New Roman'; font-size:11pt"> Prevention an</span><span style="font-family:'Times New Roman'; font-size:11pt">d</span><span style="font-family:'Times New Roman'; font-size:11pt"> Control (ECDC), which have the capacity to stimulate and coordinate global action. The Academy is pleased to see that AMR is being given a platform at the World Innovation Summit for Health (WISH) 2013</span><a name="_ftnref15"></a><a href="#_ftn15">[15]</a><span style="font-family:'Times New Roman'; font-size:11pt"> and that it is a focus of the Innovative Medicines </span><span style="font-family:'Times New Roman'; font-size:11pt">Initiative (IMI) as part of the European Union’s Horizon 2020 funding programme.</span><a name="_ftnref16"></a><a href="#_ftn16">[16]</a><span style="font-family:'Times New Roman'; font-size:11pt"> </span></li></ol><p style="line-height:14pt; margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="21" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; line-height:14pt; margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">It is paramount that consortia established to tackle antimicrobial resistance are both international and inclusive, combining representatives from the political, academic a</span><span style="font-family:'Times New Roman'; font-size:11pt">nd pharmaceutical sectors in order fully to confront the problem. </span></li></ol><p style="background-color:#ffffff; line-height:14pt; margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="22" type="1" style="margin:0pt; padding-left:0pt"><li style="background-color:#ffffff; font-family:'Times New Roman'; font-size:11pt; line-height:14pt; margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">The UK is currently working with other Commonwealth countries to set up new laboratories and new surveillance strategies in these to address AMR. These new laboratories will be paired with</span><span style="font-family:'Times New Roman'; font-size:11pt"> experienced laboratories including those in the UK, Australia, Canada and Singapore to ensure that they can make the most of their resources. Funding has been contributed by more developed countries in the Commonwealth, including the UK</span><span style="font-family:'Times New Roman'; font-size:11pt"> via the</span><span style="font-family:'Times New Roman'; font-size:11pt"> Foreign an</span><span style="font-family:'Times New Roman'; font-size:11pt">d Commonwealth Office (FCO). If such initiatives appear to be successful on evaluation, the model could be viewed as a pilot for a wider roll-out globally.    </span></li></ol><p style="background-color:#ffffff; line-height:14pt; margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="23" type="1" style="margin:0pt; padding-left:0pt"><li style="background-color:#ffffff; font-family:'Times New Roman'; font-size:11pt; line-height:14pt; margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">If the UK is to take a global lead on AMR, the Department for International Development (DfID) </span><span style="font-family:'Times New Roman'; font-size:11pt">could consider investing in developing countries’ infrastructure</span><span style="font-family:'Times New Roman'; font-size:11pt">s</span><span style="font-family:'Times New Roman'; font-size:11pt"> in order to improve surveillance. This investment could reap dividends for the UK in the form of decreased spread of AMR infections internationally in the future.   </span></li></ol><p style="font-size:11pt; line-height:115%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><h3 style="line-height:14pt; margin:0pt; page-break-after:avoid; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic; font-weight:bold">Use of antimicrobials </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic; font-weight:bold">in animals worldwide</span></h3><ol start="24" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; line-height:14pt; margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">E</span><span style="font-family:'Times New Roman'; font-size:11pt">vidence </span><span style="font-family:'Times New Roman'; font-size:11pt">suggests </span><span style="font-family:'Times New Roman'; font-size:11pt">th</span><span style="font-family:'Times New Roman'; font-size:11pt">e possibility that</span><span style="font-family:'Times New Roman'; font-size:11pt"> antimicrobial resistant infections </span><span style="font-family:'Times New Roman'; font-size:11pt">might</span><span style="font-family:'Times New Roman'; font-size:11pt"> be spread zoonotically</span><span style="font-family:'Times New Roman'; font-size:11pt">, and also from humans to </span><span style="font-family:'Times New Roman'; font-size:11pt">other </span><span style="font-family:'Times New Roman'; font-size:11pt">animals</span><span style="font-family:'Times New Roman'; font-size:11pt">, although the extent to which this takes place is currently unclear</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span><a name="_ftnref17"></a><a href="#_ftn17">[17]</a><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">,</span><a name="_ftnref18"></a><a href="#_ftn18">[18]</a><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">,</span><a name="_ftnref19"></a><a href="#_ftn19">[19]</a><span style="font-family:'Times New Roman'; font-size:11pt"> As mentioned in par</span><span style="font-family:'Times New Roman'; font-size:11pt">agraph 4, the pathways by which AMR can be selected </span><span style="font-family:'Times New Roman'; font-size:11pt">for </span><span style="font-family:'Times New Roman'; font-size:11pt">and mechanisms of </span><span style="font-family:'Times New Roman'; font-size:11pt">AMR gene </span><span style="font-family:'Times New Roman'; font-size:11pt">transfer are not fully understood, and the use of anti</span><span style="font-family:'Times New Roman'; font-size:11pt">microbials</span><span style="font-family:'Times New Roman'; font-size:11pt"> in animals </span><span style="font-family:'Times New Roman'; font-size:11pt">might contribute to</span><span style="font-family:'Times New Roman'; font-size:11pt"> human AMR infections. </span></li></ol><p style="line-height:14pt; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="25" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; line-height:14pt; margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">As such, AMR and the use of antimicrobial treatments </span><span style="font-family:'Times New Roman'; font-size:11pt">in animals should be considered with equal importance to AMR in humans. We propose that a ’One-Health’ approach—in which human and veterinary medicine are considered in parallel and in the context of environmental factors— is the best approach for addressi</span><span style="font-family:'Times New Roman'; font-size:11pt">ng AMR comprehensively.</span></li></ol><p style="line-height:14pt; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="26" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; line-height:14pt; margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">As described in paragraph 1</span><span style="font-family:'Times New Roman'; font-size:11pt">5</span><span style="font-family:'Times New Roman'; font-size:11pt">, poorly regulated use of antimicrobials in agriculture is widespread internationally, and the UK should take a leading role in promoting best practice in this regard. </span></li></ol><p style="line-height:14pt; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="27" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; line-height:14pt; margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Campaigns should also stress the </span><span style="font-family:'Times New Roman'; font-size:11pt">importance of antimicrobial use in animals to ensure animal keepers and livestock farmers are made fully aware of the implications of misuse of anti</span><span style="font-family:'Times New Roman'; font-size:11pt">microbials</span><span style="font-family:'Times New Roman'; font-size:11pt"> in animals. Farm assurance schemes such as Red Tractor</span><a name="_ftnref20"></a><a href="#_ftn20">[20]</a><span style="font-family:'Times New Roman'; font-size:11pt"> could also be promoted in collaboration w</span><span style="font-family:'Times New Roman'; font-size:11pt">ith these public antimicrobial awareness campaigns to encourage the public to choose meat from UK farms with good </span><span style="font-family:'Times New Roman'; font-size:11pt">antimicrobial</span><span style="font-family:'Times New Roman'; font-size:11pt"> practice. </span></li></ol><p style="font-size:11pt; line-height:115%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:115%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">What are the strengths and weaknesses of the Government’s 2013-2018 strategy for tackling antimicrobial resistance?</span><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps"> What changes might be made to further strengthen the Government’s action plan? </span></p><p style="font-size:11pt; line-height:115%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="28" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; line-height:14pt; margin:0pt 0pt 0pt 35.7pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">There are many strengths to the Government’s strategy: it lays out a strong domestic plan with immediate, achievable objectives, and it acknowledges the importance of many </span><span style="font-family:'Times New Roman'; font-size:11pt">key issues including research to understand underlying aspects of AMR, the development pathways for new treatments, stewardship, and the ‘One-Health’ approach to interlinking human and veterinary medicine. However, there are several areas where the strateg</span><span style="font-family:'Times New Roman'; font-size:11pt">y could be strengthened, outlined below.</span></li></ol><p style="font-size:11pt; line-height:115%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><h3 style="line-height:14pt; margin:0pt; page-break-after:avoid; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic; font-weight:bold">Funding</span></h3><ol start="29" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; line-height:14pt; margin:0pt 0pt 0pt 35.7pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">The strategy has many goals to attain if it is to be considered a success. Despite this, the financial resources to support it are unclear. The UK’s funding streams described within the strategy (approximat</span><span style="font-family:'Times New Roman'; font-size:11pt">ely £42m of existing funding, and “up to” £4 million for a new NIHR Health Protection Research Unit on AMR and Health Care Associated Infections) do not </span><span style="font-family:'Times New Roman'; font-size:11pt">accurately reflect the scale of the problem at hand. AMR is likely to be a significant drain on the NHS</span><span style="font-family:'Times New Roman'; font-size:11pt"> in the future and it is vital that appropriate funds are allocated to tackle this emerging problem. Lack of current investment may lead to larger remedial funds being required in the future if AMR increases in severity and scale. Anti</span><span style="font-family:'Times New Roman'; font-size:11pt">microbial</span><span style="font-family:'Times New Roman'; font-size:11pt"> resistant i</span><span style="font-family:'Times New Roman'; font-size:11pt">nfections are already </span><span style="font-family:'Times New Roman'; font-size:11pt">exceptionally</span><span style="font-family:'Times New Roman'; font-size:11pt"> costly to treat, with US data indicating</span><span style="font-family:'Times New Roman'; font-size:11pt"> that </span><span style="font-family:'Times New Roman'; font-size:11pt">these may</span><span style="font-family:'Times New Roman'; font-size:11pt"> generate</span><span style="font-family:'Times New Roman'; font-size:11pt"> as much as</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">$20 billion in excess healthcare costs</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><a name="_ftnref21"></a><a href="#_ftn21">[21]</a><span style="font-family:'Times New Roman'; font-size:11pt"> </span></li></ol><p style="font-size:11pt; line-height:115%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:115%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic; font-weight:bold">Pharmaceutical incentives </span></p><ol start="30" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; line-height:14pt; margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Pharmaceutical companies will clearly be instrumental </span><span style="font-family:'Times New Roman'; font-size:11pt">in</span><span style="font-family:'Times New Roman'; font-size:11pt"> achieving many of</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">the </span><span style="font-family:'Times New Roman'; font-size:11pt">goals set out in the strategy. However, the list of objectives outlined for these companies is not supplemented with incentives for them to achieve them. As described in paragraphs 8 to 1</span><span style="font-family:'Times New Roman'; font-size:11pt">0</span><span style="font-family:'Times New Roman'; font-size:11pt">, the production of new antimicrobials may no longer be profita</span><span style="font-family:'Times New Roman'; font-size:11pt">ble for pharmaceutical companies. These companies have a responsibility to their shareholders to make a profit on their products, and therefore may not produce future antimicrobial products based </span><span style="font-family:'Times New Roman'; font-size:11pt">simply </span><span style="font-family:'Times New Roman'; font-size:11pt">on the public health imperative to do so. </span><span style="font-family:'Times New Roman'; font-size:11pt">In situatio</span><span style="font-family:'Times New Roman'; font-size:11pt">ns of gravity, such as this, governments and drug companies have often collaborated, and more emphasis on this is required for the strategy’s goals to be achieved. </span></li></ol><p style="line-height:14pt; margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><h3 style="line-height:14pt; margin:0pt; page-break-after:avoid; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic; font-weight:bold">Global perspective</span></h3><ol start="31" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; line-height:14pt; margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">In order for this strategy to achieve its objectives, it must be more g</span><span style="font-family:'Times New Roman'; font-size:11pt">lobally focussed. Even with best practice in containing AMR being used in the UK, AMR infections will enter our population from overseas. As described in paragraph 1</span><span style="font-family:'Times New Roman'; font-size:11pt">6</span><span style="font-family:'Times New Roman'; font-size:11pt">, international migration is a </span><span style="font-family:'Times New Roman'; font-size:11pt">potentially huge</span><span style="font-family:'Times New Roman'; font-size:11pt"> contributor to the spread of </span><span style="font-family:'Times New Roman'; font-size:11pt">AMR</span><span style="font-family:'Times New Roman'; font-size:11pt"> organisms</span><span style="font-family:'Times New Roman'; font-size:11pt">, but this is largely overlooked in the strategy. </span></li></ol><p style="line-height:14pt; margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="32" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; line-height:14pt; margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">As already highlighted, it is vital that the strategy brings its objectives to the world stage and ensures that bad practices that encourage AMR, such as over-the-counter anti</span><span style="font-family:'Times New Roman'; font-size:11pt">microbial </span><span style="font-family:'Times New Roman'; font-size:11pt">sales and extensive</span><span style="font-family:'Times New Roman'; font-size:11pt"> and poorly regulated use of anti</span><span style="font-family:'Times New Roman'; font-size:11pt">microbial</span><span style="font-family:'Times New Roman'; font-size:11pt">s in agriculture in some parts of the world, are ceased.</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">The UK’s participation in global forums on AMR should be seen as an opportunity to inform those who do not regulate antimicrobials appropriately</span><span style="font-family:'Times New Roman'; font-size:11pt">,</span><span style="font-family:'Times New Roman'; font-size:11pt"> and ensure that there is awareness of the problems that these stand to create if these practices are maintained.</span><span style="font-family:'Times New Roman'; font-size:11pt"> However, the complexity of this issue must be acknowledged; for example, in some countries without universal health coverage, cheap over-the-c</span><span style="font-family:'Times New Roman'; font-size:11pt">ounter antimicrobials can have very beneficial health effects for individuals that may not be able to afford doctors’ consultation fees.</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span></li></ol><p style="font-size:11pt; line-height:115%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="font-size:11pt; line-height:115%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic; font-weight:bold">Inclusion of other microbes</span></p><ol start="33" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; line-height:14pt; margin:0pt 0pt 0pt 35.7pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">The exclusive focus of the strategy on bacterial antibiotic resistance is understandable </span><span style="font-family:'Times New Roman'; font-size:11pt">given its wider public recognition compared to AMR in other microbes, but AMR in fungi, viruses and parasites should not be overlooked at this stage. This will only serve to create a crisis point in the future for life-threatening infections from these org</span><span style="font-family:'Times New Roman'; font-size:11pt">anisms. Antifungal resistance, for example, is already an emerging problem </span><span style="font-family:'Times New Roman'; font-size:11pt">because</span><span style="font-family:'Times New Roman'; font-size:11pt"> excessive use of triazoles for the prevention of fungal infection in the agricultural </span><span style="font-family:'Times New Roman'; font-size:11pt">sector has led to triazole resistant fungal infections in humans.</span><a name="_ftnref22"></a><a href="#_ftn22">[22]</a><span style="font-family:'Times New Roman'; font-size:11pt"> This bad practice, i</span><span style="font-family:'Times New Roman'; font-size:11pt">f continued, will result in an antifungal situation </span><span style="font-family:'Times New Roman'; font-size:11pt">that</span><span style="font-family:'Times New Roman'; font-size:11pt"> mirrors the anti</span><span style="font-family:'Times New Roman'; font-size:11pt">biotic</span><span style="font-family:'Times New Roman'; font-size:11pt"> resistance landscape. The antifungal drug pool is significantly smaller than the antibiotic pool and therefore resistance will develop more quickly and will have a profound eff</span><span style="font-family:'Times New Roman'; font-size:11pt">ect on treatment of many conditions.</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span></li></ol><p style="line-height:14pt; margin:0pt 0pt 0pt 35.7pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">The growing number of effective antiviral drugs in use</span><span style="font-family:'Times New Roman'; font-size:11pt"> also illustrate</span><span style="font-family:'Times New Roman'; font-size:11pt">s</span><span style="font-family:'Times New Roman'; font-size:11pt"> this point</span><span style="font-family:'Times New Roman'; font-size:11pt">. In many cases their development has been catalysed by the HIV pandemic, but these are finding application in the treatment of importan</span><span style="font-family:'Times New Roman'; font-size:11pt">t persistent viral pathogens in addition to HIV, such as </span><span style="font-family:'Times New Roman'; font-size:11pt">h</span><span style="font-family:'Times New Roman'; font-size:11pt">epatitis C. New antivirals against influenza virus are also being used at the population level. This increasing and widespread use of antiviral drugs will inevitably be accompanied by the growing em</span><span style="font-family:'Times New Roman'; font-size:11pt">ergence of AMR in viruses (as already seen for HIV).</span><a name="_ftnref23"></a><a href="#_ftn23">[23]</a><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">Thus many of the proposals outlined in the strategy may be equally applied to responses to resistance in organisms besides bacteria, and these should be given appropriate weighting in the strategy’s obj</span><span style="font-family:'Times New Roman'; font-size:11pt">ectives. </span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">For brevity, we have not addressed each aspect of AMR (such as</span><span style="font-family:'Times New Roman'; font-size:11pt"> occurrences in</span><span style="font-family:'Times New Roman'; font-size:11pt"> virology</span><span style="font-family:'Times New Roman'; font-size:11pt">, mycology and </span><span style="font-family:'Times New Roman'; font-size:11pt">parasitology) in detail individually in this response, but would be willing to provide further information to the committee </span><span style="font-family:'Times New Roman'; font-size:11pt">if </span><span style="font-family:'Times New Roman'; font-size:11pt">request</span><span style="font-family:'Times New Roman'; font-size:11pt">ed</span><span style="font-family:'Times New Roman'; font-size:11pt">.  </span></p><p style="font-size:11pt; line-height:115%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">&#xa0;</span></p><p style="font-size:11pt; line-height:115%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">November 2013</span></p><p style="margin:0pt"><span style="font-family:Verdana; font-size:10pt">&#xa0;</span></p></div><hr style="width:33%; height:1px; text-align:left" /><p style="margin:0pt 0pt 0pt 7.1pt; text-indent:-7.1pt"><a name="_ftn1"></a><a href="#_ftnref1">[1]</a><span style="font-family:Verdana; font-size:8pt"> </span><span style="font-family:Verdana; font-size:8pt">              </span><span style="font-family:Verdana; font-size:8pt">The Department of Health (2013). </span><span style="font-family:Verdana; font-size:8pt; font-style:italic">UK </span><span style="font-family:Verdana; font-size:8pt; font-style:italic">Five year Antimicrobial resistance Strategy 2013-2015</span><span style="font-family:Verdana; font-size:8pt">.   </span><a href="https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/244058/20130902_UK_5_year_AMR_strategy.pdf"><span style="color:#0000ff; font-family:Verdana; font-size:8pt; text-decoration:underline">https://www.gov.uk/government/uploads/system/uploads/attachment_data/</span><span style="color:#0000ff; font-family:Verdana; font-size:8pt; text-decoration:underline">file/244058/20130902_UK_5_year_AMR_strategy.pdf</span></a></p><p style="margin:0pt 0pt 0pt 7.1pt; text-indent:-7.1pt"><a name="_ftn2"></a><a href="#_ftnref2">[2]</a><span style="font-family:Verdana; font-size:8pt"> </span><span style="font-family:Verdana; font-size:8pt">              </span><span style="font-family:Verdana; font-size:8pt">Tzouvelekis L</span><span style="font-family:Verdana; font-size:8pt">S</span><span style="font-family:Verdana; font-size:8pt">,</span><span style="font-family:Verdana; font-size:8pt"> </span><span style="font-family:Verdana; font-size:8pt; font-style:italic">et al.</span><span style="font-family:Verdana; font-size:8pt"> (2012). </span><span style="font-family:Verdana; font-size:8pt; font-style:italic">Carbapenemases in Klebsiella pneumoniae and Other Enterobacteriaceae: an Evolving Crisis of Global Dimensions.</span><span style="font-family:Verdana; font-size:8pt"> Clinical Microbiology Reviews</span><span style="font-family:Verdana; font-size:8pt"> </span><span style="font-family:Verdana; font-size:8pt; font-weight:bold">25(4)</span><span style="font-family:Verdana; font-size:8pt">, 682-707. </span></p><h1 style="background-color:#ffffff; margin:0pt 0pt 0pt 7.1pt; page-break-after:avoid; text-indent:-7.1pt"><a name="_ftn3"></a><a href="#_ftnref3">[3]</a><span style="font-family:Verdana; font-size:8pt; font-weight:normal"> </span><span style="font-family:Verdana; font-size:8pt; font-weight:normal">              </span><span style="font-family:Verdana; font-size:8pt; font-weight:normal">The Health</span><span style="font-family:Verdana; font-size:8pt; font-weight:normal"> Protection Agency (2012). </span><span style="font-family:Verdana; font-size:8pt; font-style:italic; font-weight:normal">English National Point Prevalence Survey on Healthcare-associated Infections and Antimicrobial Use, 2011: preliminary data.</span></h1><p style="margin:0pt 0pt 0pt 7.1pt"><a href="http://www.hpa.org.uk/Publications/InfectiousDiseases/AntimicrobialAndHealthcareAssociatedInfections/1205HCAIEnglishPPSforhcaiandamu2011prelim/"><span style="color:#0000ff; font-family:Verdana; font-size:8pt; text-decoration:underline">http://www.hpa.org.uk/Publications/InfectiousDiseases/AntimicrobialAndHealthcareAssociatedInfections/1205HCAIEnglishPPSforhcaiandamu2011prelim/</span></a></p><p style="margin:0pt 0pt 0pt 7.1pt; text-indent:-7.1pt"><a name="_ftn4"></a><a href="#_ftnref4">[4]</a><span style="font-family:Verdana; font-size:8pt"> Pallares R</span><span style="font-family:Verdana; font-size:8pt">,</span><span style="font-family:Verdana; font-size:8pt"> </span><span style="font-family:Verdana; font-size:8pt; font-style:italic">et al</span><span style="font-family:Verdana; font-size:8pt">. (1995). </span><span style="font-family:Verdana; font-size:8pt; font-style:italic">Resistance to Penicillin and</span><span style="font-family:Verdana; font-size:8pt; font-style:italic"> Cephalosporin and Mortality from Severe Pneumococcal Pneumonia in Barcelona, Spain</span><span style="font-family:Verdana; font-size:8pt">. N</span><span style="font-family:Verdana; font-size:8pt">ew</span><span style="font-family:Verdana; font-size:8pt"> Engl</span><span style="font-family:Verdana; font-size:8pt">and</span><span style="font-family:Verdana; font-size:8pt"> J</span><span style="font-family:Verdana; font-size:8pt">ournal of</span><span style="font-family:Verdana; font-size:8pt"> Med</span><span style="font-family:Verdana; font-size:8pt">icine</span><span style="font-family:Verdana; font-size:8pt"> </span><span style="font-family:Verdana; font-size:8pt; font-weight:bold">333</span><span style="font-family:Verdana; font-size:8pt; font-weight:bold">, </span><span style="font-family:Verdana; font-size:8pt">474-480</span><span style="font-family:Verdana; font-size:8pt">.</span></p><p style="margin:0pt"><a name="_ftn5"></a><a href="#_ftnref5">[5]</a><span style="font-family:Verdana; font-size:8pt"> </span><span style="font-family:Verdana; font-size:8pt">For more information:</span><span style="font-family:Verdana; font-size:8pt"> </span><a href="http://www.hmpdacc.org/"><span style="color:#0000ff; font-family:Verdana; font-size:8pt; text-decoration:underline">http://www.hmpdacc.org/</span></a></p><p style="margin:0pt 0pt 0pt 7.1pt; text-indent:-7.1pt"><a name="_ftn6"></a><a href="#_ftnref6">[6]</a><span style="font-family:Verdana; font-size:8pt"> Morten</span><span style="font-family:Verdana; font-size:8pt"> </span><span style="font-family:Verdana; font-size:8pt">OA</span><span style="font-family:Verdana; font-size:8pt">,</span><span style="font-family:Verdana; font-size:8pt"> </span><span style="font-family:Verdana; font-size:8pt; font-style:italic">et al. </span><span style="font-family:Verdana; font-size:8pt">(2009) </span><span style="font-family:Verdana; font-size:8pt; font-style:italic">Functional</span><span style="font-family:Verdana; font-size:8pt; font-style:italic"> characterization of the antibiotic resistance reservoir in the human microflora. </span><span style="font-family:Verdana; font-size:8pt">Science </span><span style="font-family:Verdana; font-size:8pt; font-weight:bold">325</span><span style="font-family:Verdana; font-size:8pt; font-weight:bold"> (5944)</span><span style="font-family:Verdana; font-size:8pt">,</span><span style="font-family:Verdana; font-size:8pt"> 1128-1131</span><span style="font-family:Verdana; font-size:8pt">.</span></p><p style="margin:0pt 0pt 0pt 7.1pt; text-indent:-7.1pt"><a name="_ftn7"></a><a href="#_ftnref7">[7]</a><span style="font-family:Verdana; font-size:8pt"> </span><span style="font-family:Verdana; font-size:8pt">Foxman </span><span style="font-family:Verdana; font-size:8pt">B </span><span style="font-family:Verdana; font-size:8pt">&amp;</span><span style="font-family:Verdana; font-size:8pt"> Rosenthal</span><span style="font-family:Verdana; font-size:8pt"> M.</span><span style="font-family:Verdana; font-size:8pt"> (2013)</span><span style="font-family:Verdana; font-size:8pt; font-style:italic">. Implications of the Human Microbiome Project for epidemiology</span><span style="font-family:Verdana; font-size:8pt">. Am</span><span style="font-family:Verdana; font-size:8pt">erican</span><span style="font-family:Verdana; font-size:8pt"> J</span><span style="font-family:Verdana; font-size:8pt">ournal of</span><span style="font-family:Verdana; font-size:8pt"> Epidemiol</span><span style="font-family:Verdana; font-size:8pt">ogy</span><span style="font-family:Verdana; font-size:8pt">. </span><span style="font-family:Verdana; font-size:8pt; font-weight:bold">177(3)</span><span style="font-family:Verdana; font-size:8pt; font-weight:bold">,</span><span style="font-family:Verdana; font-size:8pt"> 197-201.</span></p><p style="margin:0pt 0pt 0pt 7.1pt; text-indent:-7.1pt"><a name="_ftn8"></a><a href="#_ftnref8">[8]</a><span style="font-family:Verdana; font-size:8pt"> The Institute of Medicine (2000)</span><span style="font-family:Verdana; font-size:8pt">.</span><span style="font-family:Verdana; font-size:8pt"> </span><span style="font-family:Verdana; font-size:8pt; font-style:italic">Vaccines for the 21st Century: a tool for decision making</span><span style="font-family:Verdana; font-size:8pt">.  </span><a href="http://www.nap.edu/catalog.php?record_id=5501"><span style="color:#0000ff; font-family:Verdana; font-size:8pt; text-decoration:underline">http://www.nap.edu/catalog.php?record_id=5501</span></a><span style="font-family:Verdana; font-size:8pt">  </span></p><p style="margin:0pt 0pt 0pt 7.1pt; text-indent:-7.1pt"><a name="_ftn9"></a><a href="#_ftnref9">[9]</a><span style="font-family:Verdana; font-size:8pt"> </span><span style="font-family:Verdana; font-size:8pt">              </span><span style="font-family:Verdana; font-size:8pt">For more information:</span><span style="font-family:Verdana; font-size:8pt"> </span><a href="http://ecdc.europa.eu/en/EAAD/"><span style="color:#0000ff; font-family:Verdana; font-size:8pt; text-decoration:underline">http://ecdc.europa.eu/en/EAAD/</span></a></p><p style="margin:0pt 0pt 0pt 7.1pt; text-indent:-7.1pt"><a name="_ftn10"></a><a href="#_ftnref10">[10]</a><span style="font-family:Verdana; font-size:8pt"> Coenen S</span><span style="font-family:Verdana; font-size:8pt">,</span><span style="font-family:Verdana; font-size:8pt"> </span><span style="font-family:Verdana; font-size:8pt; font-style:italic">et al.</span><span style="font-family:Verdana; font-size:8pt">  (2013)</span><span style="font-family:Verdana; font-size:8pt">.</span><span style="font-family:Verdana; font-size:8pt"> </span><span style="font-family:Verdana; font-size:8pt; font-style:italic">Are patient views about antibiotics related to clinician perceptions, management and outcome? A multi-country study in outpatients with acute cough. </span><span style="font-family:Verdana; font-size:8pt">PLoS One</span><span style="font-family:Verdana; font-size:8pt; font-style:italic"> </span><span style="font-family:Verdana; font-size:8pt; font-weight:bold">8(10)</span><span style="font-family:Verdana; font-size:8pt; font-weight:bold">,</span><span style="background-color:#ffffff; font-family:Verdana; font-size:8pt">&#xa0;</span><span style="background-color:#ffffff; font-family:Verdana; font-size:8pt">e76691</span><span style="background-color:#ffffff; font-family:Verdana; font-size:8pt">.</span></p><p style="margin:0pt 0pt 0pt 7.1pt; text-indent:-7.1pt"><a name="_ftn11"></a><a href="#_ftnref11">[11]</a><span style="font-family:Verdana; font-size:8pt"> </span><span style="font-family:Verdana; font-size:8pt">For more information:</span><span style="font-family:Verdana; font-size:8pt"> </span><a href="http://www.rcgp.org.uk/targetantibiotics/"><span style="color:#0000ff; font-family:Verdana; font-size:8pt; text-decoration:underline">http://www.rcgp.org.uk/targetantibiotics/</span></a></p><p style="margin:0pt 0pt 0pt 7.1pt; text-indent:-7.1pt"><a name="_ftn12"></a><a href="#_ftnref12">[12]</a><span style="font-family:Verdana; font-size:8pt"> </span><span style="font-family:Verdana; font-size:8pt">For more information: </span><a href="http://www.stemmingthetide.org/"><span style="color:#0000ff; font-family:Verdana; font-size:8pt; text-decoration:underline">http://www.stemmingthetide.org/</span></a></p><p style="margin:0pt 0pt 0pt 7.1pt; text-indent:-7.1pt"><a name="_ftn13"></a><a href="#_ftnref13">[13]</a><span style="font-family:Verdana; font-size:8pt"> </span><span style="font-family:Verdana; font-size:8pt">The World Health Organization (2002) </span><span style="font-family:Verdana; font-size:8pt; font-style:italic">Impacts of antimicrobial growth promoter termination in Denmark</span><span style="font-family:Verdana; font-size:8pt">. </span><a href="http://www.who.int/gfn/en/Expertsreportgrowthpromoterdenmark.pdf"><span style="color:#0000ff; font-family:Verdana; font-size:8pt; text-decoration:underline">http://www.who.int/gfn/en/Expertsreportgrowthpromoterdenmark.pdf</span></a></p><p style="margin:0pt 0pt 0pt 7.1pt; text-indent:-7.1pt"><a name="_ftn14"></a><a href="#_ftnref14">[14]</a><span style="font-family:Verdana; font-size:8pt"> </span><span style="font-family:Verdana; font-size:8pt">For mo</span><span style="font-family:Verdana; font-size:8pt">re information: </span><a href="http://www1.imperial.ac.uk/medicine/about/institutes/cipm/centre_outputs/antimicrobialstewardship/"><span style="color:#0000ff; font-family:Verdana; font-size:8pt; text-decoration:underline">http://www1.imperial.ac.uk/medicine/about/institutes/cipm/centre_outputs/antimicrobialstewardship/</span></a><span style="font-family:Verdana; font-size:8pt"> </span></p><p style="margin:0pt"><a name="_ftn15"></a><a href="#_ftnref15">[15]</a><span style="font-family:Verdana; font-size:8pt"> </span><span style="font-family:Verdana; font-size:8pt">For more information: </span><a href="http://www.wish-qatar.org/forums/antimicrobial-resistance"><span style="color:#0000ff; font-family:Verdana; font-size:8pt; text-decoration:underline">http://www.wish-qatar.org/forums/antimicrobial-resistance</span></a></p><p style="margin:0pt 0pt 0pt 7.1pt; text-indent:-7.1pt"><a name="_ftn16"></a><a href="#_ftnref16">[16]</a><span style="font-family:Verdana; font-size:8pt"> </span><span style="font-family:Verdana; font-size:8pt">The </span><span style="font-family:Verdana; font-size:8pt">European Union (2013)</span><span style="font-family:Verdana; font-size:8pt">.</span><span style="font-family:Verdana; font-size:8pt"> </span><span style="font-family:Verdana; font-size:8pt; font-style:italic">Proposal for a Council Regulation  for the Innovative Medicines Initiative 2 Joint  Undertaking</span><span style="font-family:Verdana; font-size:8pt">. </span><a href="http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=COM:2013:0495:FIN:en:PDF"><span style="color:#0000ff; font-family:Verdana; font-size:8pt; text-decoration:underline">http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=COM:2013:0495:FIN:en:PDF</span></a></p><p style="margin:0pt 0pt 0pt 7.1pt; text-indent:-7.1pt"><a name="_ftn17"></a><a href="#_ftnref17">[17]</a><span style="font-family:Verdana; font-size:8pt"> Sing A</span><span style="font-family:Verdana; font-size:8pt">,</span><span style="font-family:Verdana; font-size:8pt"> </span><span style="font-family:Verdana; font-size:8pt; font-style:italic">et al. </span><span style="font-family:Verdana; font-size:8pt">(2008)</span><span style="font-family:Verdana; font-size:8pt">.</span><span style="font-family:Verdana; font-size:8pt"> </span><span style="font-family:Verdana; font-size:8pt; font-style:italic">Methicillin-resistant </span><span style="font-family:Verdana; font-size:8pt">Staphylococcus aureus</span><span style="font-family:Verdana; font-size:8pt; font-style:italic"> in a family</span><span style="font-family:Verdana; font-size:8pt; font-style:italic"> and its pet cat</span><span style="font-family:Verdana; font-size:8pt">.</span><span style="font-family:Verdana; font-size:8pt"> </span><span style="font-family:Verdana; font-size:8pt">N</span><span style="font-family:Verdana; font-size:8pt">ew</span><span style="font-family:Verdana; font-size:8pt"> Engl</span><span style="font-family:Verdana; font-size:8pt">and</span><span style="font-family:Verdana; font-size:8pt"> J</span><span style="font-family:Verdana; font-size:8pt">ournal of </span><span style="font-family:Verdana; font-size:8pt">Med</span><span style="font-family:Verdana; font-size:8pt">icine</span><span style="font-family:Verdana; font-size:8pt"> </span><span style="font-family:Verdana; font-size:8pt; font-weight:bold">358</span><span style="font-family:Verdana; font-size:8pt">,</span><span style="font-family:Verdana; font-size:8pt">1200-1201</span><span style="font-family:Verdana; font-size:8pt">.</span></p><p style="margin:0pt 0pt 0pt 7.1pt; text-indent:-7.1pt"><a name="_ftn18"></a><a href="#_ftnref18">[18]</a><span style="font-family:Verdana; font-size:8pt"> van Duijkeren E, </span><span style="font-family:Verdana; font-size:8pt; font-style:italic">et al</span><span style="font-family:Verdana; font-size:8pt">. (2005)</span><span style="font-family:Verdana; font-size:8pt">.</span><span style="font-family:Verdana; font-size:8pt"> </span><span style="font-family:Verdana; font-size:8pt; font-style:italic">Transmission of a Panton-Valentine leucocidin-positive, Methicillin-resistant </span><span style="font-family:Verdana; font-size:8pt">Staphylococcus aureus</span><span style="font-family:Verdana; font-size:8pt; font-style:italic"> strain between humans and a dog.</span><span style="font-family:Verdana; font-size:8pt"> J</span><span style="font-family:Verdana; font-size:8pt">ournal of</span><span style="font-family:Verdana; font-size:8pt"> Clin</span><span style="font-family:Verdana; font-size:8pt">ical</span><span style="font-family:Verdana; font-size:8pt"> Micr</span><span style="font-family:Verdana; font-size:8pt">obiol</span><span style="font-family:Verdana; font-size:8pt">ogy</span><span style="font-family:Verdana; font-size:8pt">&#xa0;</span><span style="font-family:Verdana; font-size:8pt; font-weight:bold">43(12)</span><span style="font-family:Verdana; font-size:8pt; font-weight:bold">,</span><span style="font-family:Verdana; font-size:8pt"> 6209–6211</span><span style="background-color:#ffffff; font-family:Verdana; font-size:8pt">.</span></p><h1 style="background-color:#ffffff; margin:0pt 0pt 0pt 7.1pt; page-break-after:avoid; text-indent:-7.1pt"><a name="_ftn19"></a><a href="#_ftnref19">[19]</a><span style="font-family:Verdana; font-size:8pt; font-weight:normal"> Mather AE</span><span style="font-family:Verdana; font-size:8pt; font-weight:normal">,</span><span style="font-family:Verdana; font-size:8pt; font-weight:normal"> </span><span style="font-family:Verdana; font-size:8pt; font-style:italic; font-weight:normal">et al. </span><span style="font-family:Verdana; font-size:8pt; font-weight:normal">(2013)</span><span style="font-family:Verdana; font-size:8pt; font-weight:normal">.</span><span style="font-family:Verdana; font-size:8pt; font-weight:normal"> </span><span style="font-family:Verdana; font-size:8pt; font-style:italic; font-weight:normal">Distinguishable epidemics of multidrug-resistant</span><span style="font-family:Verdana; font-size:8pt; font-style:italic; font-weight:normal">&#xa0;</span><span style="font-family:Verdana; font-size:8pt; font-style:normal; font-weight:normal">Salmonella </span><span style="font-family:Verdana; font-size:8pt; font-style:italic; font-weight:normal">t</span><span style="font-family:Verdana; font-size:8pt; font-weight:normal">yphimurium</span><span style="font-family:Verdana; font-size:8pt; font-style:italic; font-weight:normal"> DT104 in different hosts</span><span style="font-family:Verdana; font-size:8pt; font-weight:normal">. Science, </span><span style="font-family:Verdana; font-size:8pt; font-weight:bold">341(6153)</span><span style="font-family:Verdana; font-size:8pt; font-weight:normal">,</span><span style="font-family:Verdana; font-size:8pt; font-weight:normal"> 1514-17.</span></h1><p style="margin:0pt"><a name="_ftn20"></a><a href="#_ftnref20">[20]</a><span style="font-family:Verdana; font-size:8pt"> </span><span style="font-family:Verdana; font-size:8pt">For more information: </span><a href="http://www.redtractor.org.uk/home"><span style="color:#0000ff; font-family:Verdana; font-size:8pt; text-decoration:underline">http://www.redtractor.org.uk/home</span></a></p><p style="margin:0pt 0pt 0pt 7.1pt; text-indent:-7.1pt"><a name="_ftn21"></a><a href="#_ftnref21">[21]</a><span style="font-family:Verdana; font-size:8pt"> The US Centers for Disease Control and Prevention (2013)</span><span style="font-family:Verdana; font-size:8pt">.</span><span style="font-family:Verdana; font-size:8pt"> </span><span style="font-family:Verdana; font-size:8pt; font-style:italic">Antibiotic resistance threats in the United States.</span><span style="font-family:Verdana; font-size:8pt"> </span><a href="http://www.cdc.gov/drugresistance/threat-report-2013/pdf/ar-threats-2013-508.pdf"><span style="color:#0000ff; font-family:Verdana; font-size:8pt; text-decoration:underline">http://www.cd</span><span style="color:#0000ff; font-family:Verdana; font-size:8pt; text-decoration:underline">c.gov/drugresistance/threat-report-2013/pdf/ar-threats-2013-508.pdf</span></a></p><p style="margin:0pt 0pt 0pt 7.1pt; text-indent:-7.1pt"><a name="_ftn22"></a><a href="#_ftnref22">[22]</a><span style="font-family:Verdana; font-size:8pt"> The European Centre for Disease Prevention and Control (2013). </span><span style="font-family:Verdana; font-size:8pt; font-style:italic">Risk assessment o</span><span style="font-family:Verdana; font-size:8pt; font-style:italic">n environmental use of </span><span style="font-family:Verdana; font-size:8pt; font-style:italic">triazoles</span><span style="font-family:Verdana; font-size:8pt">. </span></p><p style="margin:0pt 0pt 0pt 7.1pt"><a href="http://www.ecdc.europa.eu/en/publications/publications/risk-assessment-impact-environmental-usage-of-triazoles-on-aspergillus-spp-resistance-to-medical-triazoles.pdf"><span style="color:#0000ff; font-family:Verdana; font-size:8pt; text-decoration:underline">http://www.ecdc.europa.eu/en/publications/publications/risk-assessment-impact-environmental-usage-of-triazoles-on-aspergillus-spp-resistance-to-m</span><span style="color:#0000ff; font-family:Verdana; font-size:8pt; text-decoration:underline">edical-triazoles.pdf</span></a></p><p style="margin:0pt 0pt 0pt 7.1pt; text-indent:-7.1pt"><a name="_ftn23"></a><a href="#_ftnref23">[23]</a><span style="font-family:Verdana; font-size:8pt"> The World Health Organization (2008) </span><span style="font-family:Verdana; font-size:8pt; font-style:italic">HIV Drug resistance fact sheet.</span><span style="font-family:Verdana; font-size:8pt; font-style:italic"> </span><a href="http://www.who.int/hiv/facts/drug_resistance/en/"><span style="color:#0000ff; font-family:Verdana; font-size:8pt; text-decoration:underline">http://www.who.int/hiv/facts/drug_resistance/en/</span></a></p></body></html>